Menu Search
Equities

Tianjin TEDA Biomedical Engineering Co Ltd

8189:HKG.HZ

Tianjin TEDA Biomedical Engineering Co Ltd

Actions
  • Price (HKD)0.22
  • Today's Change0.00 / 0.00%
  • Shares traded270.00k
  • 1 Year change+144.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 05:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Tianjin TEDA Biomedical Engineering Co Ltd had relatively flat revenues (403.73m to 398.00m), though the company grew net income from a loss of 27.45m to a smaller loss of 20.16m. A reduction in the cost of goods sold as a percentage of sales from 96.33% to 94.63% was a component in the net income growth despite flat revenues.
Gross margin6.29%
Net profit margin-0.57%
Operating margin3.17%
Return on assets-0.75%
Return on equity-13.86%
Return on investment-2.83%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Tianjin TEDA Biomedical Engineering Co Ltd fell by 893.31k. Cash Flow from Financing totalled 12.73m or 3.20% of revenues. In addition the company used 13.15m for operations while cash used for investing totalled 467.44k.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.026
Tangible book value per share0.026
More ▼

Balance sheet in CNYView more

Tianjin TEDA Biomedical Engineering Co Ltd has a Debt to Total Capital ratio of 65.18%, a higher figure than the previous year's 57.36%.
Current ratio0.894
Quick ratio0.536
Total debt/total equity2.41
Total debt/total capital0.6518
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.